BTK IN-1
CAS: 1270014-40-8
Ref. 3D-VAC01440
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Product Information
BTK IN-1 is a novel antibody drug conjugate (ADC) that targets the BTK protein and is being developed for the treatment of chronic lymphocytic leukemia. The BTK protein is expressed in cells of the microenvironment where cancerous cells are found, and when activated, it can lead to cancer cell proliferation. Clinical data has shown that BTK IN-1 reduces plasma concentrations of BTK, which might be an indication that this ADC is specific to the target. In addition, clinical development has been conducted on patients with lymphocytic leukemia or chronic lymphocytic leukemia. According to these clinical studies, BTK IN-1 appears to be an effective drug against cancerous cells in the blood and bone marrow.
Chemical properties
Technical inquiry about: 3D-VAC01440 BTK IN-1
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
